This is an Insight article, written by a selected contributor as part of GIR's co-published content. Read more on Insight US enforcement authorities have several options available to them in resolving Foreign Corrupt Practices Act (FCPA) investigations – among them imposing an independent compliance monitor to oversee the company’s anti-bribery and anti-corruption compliance programme. Historically, FCPA investigations have frequently resulted in the imposition of compliance monitorships.
Miranda Hooker
Arlington
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Miranda Hooker
HHS-OIG Announces an Audit of Medicare Payments for Chronic Care Management Services and Signals It Remains an Enforcement Priority
On March 16, 2026, the Office of Inspector General for the US Department of Health and Human Services (HHS-OIG) announced an audit of Medicare Part B payments for chronic care management (CCM) services. The audit will specifically examine whether beneficiaries who are receiving CCM services meet the Medicare eligibility requirement that they suffer from multiple chronic conditions.
HHS-OIG Announces an Audit of Medicare Payments for Chronic Care Management Services and Signals It Remains an Enforcement Priority
On March 16, 2026, the Office of Inspector General for the US Department of Health and Human Services (HHS-OIG) announced an audit of Medicare Part B payments for chronic care management (CCM) services. The audit will specifically examine whether beneficiaries who are receiving CCM services meet the Medicare eligibility requirement that they suffer from multiple chronic conditions.
Fifth Circuit Adopts Narrow Interpretation Of Two Critical DEA Regulations
Ilene Albala’s articles from Goodwin Procter LLP are most popular: within Food, Drugs, Healthcare and Life Sciences topic(s) in United States Goodwin Procter LLP are most popular: within Criminal Law, Immigration and Cannabis & Hemp topic(s) On February 13, 2026, the Fifth Circuit issued a unanimous panel opinion holding that the Drug Enforcement Agency ("DEA") misinterpreted two of its pivotal regulations — its "corresponding responsibility" (21 C.F.R. § 1306.04(a)) and "usual course of...
Health Headlines: January 2026
Ilene Albala’s articles from Goodwin Procter LLP are most popular: within Food, Drugs, Healthcare and Life Sciences topic(s) with Finance and Tax Executives in United States On January 22, 2026, the House of Representatives passed HR 7148, an appropriations package that would finance the U.S. Department of Health and Human Services and other agencies.
Historic False Claims Act Enforcement Illustrates Trump Administration's Focus On Healthcare Fraud
Goodwin Procter LLP are most popular: within Immigration, Criminal Law and Cannabis & Hemp topic(s) False Claims Act enforcement reached yet another record high in 2025. On January 16, 2026, the U.S. Department of Justice ("DOJ") announced that settlements and judgments under the False Claims Act ("FCA") reached a record-breaking $6.8 billion in Fiscal Year 2025. This is more than twice the amount of FCA settlements and judgments in FY 2024, around $2.9 billion.
Historic False Claims Act Enforcement Illustrates Trump Administration’s Focus on Healthcare Fraud
False Claims Act enforcement reached yet another record high in 2025. On January 16, 2026, the U.S. Department of Justice (“DOJ”) announced that settlements and judgments under the False Claims Act (“FCA”) reached a record-breaking $6.8 billion in Fiscal Year 2025. This is more than twice the amount of FCA settlements and judgments in FY 2024, around $2.9 billion. Relators brought 1,297 qui tam lawsuits in FY 2025, also an all-time high and a big increase over FY 2024’s 979 qui tams.
Trump Administration Unveils New National Fraud Enforcement Division Of DOJ
Ilene Albala’s articles from Goodwin Procter LLP are most popular: in United States Goodwin Procter LLP are most popular: within Transport, Cannabis & Hemp and Strategy topic(s) On Thursday, January 8, 2026, the Trump administration unveiled the creation of a new division within the Department of Justice (DOJ) to combat fraud on the federal government.
Miranda Hooker Named a 2025 Top Woman of Law in Massachusetts
Partner Miranda Hooker was named one of Massachusetts Lawyers Weekly’s 2025 Top Women of Law. This honor celebrates the exceptional accomplishments of women attorneys as leaders, educators, and mentors, as well as their pro bono, social justice, advocacy, and business efforts. Miranda is a partner in the firm’s Complex Litigation & Dispute Resolution group, and serves as Co-Chair of the Government Investigations, Enforcement & White Collar Defense practice.
DOJ-HHS Announces False Claims Act Working Group, Emphasizes Healthcare Fraud Enforcement Priorities
The Trump administration recently announced the renewal of a new cross-agency collaboration between the Department of Justice (DOJ) and the Department of Health and Human Services (HHS) in the form of the DOJ-HHS False Claims Act Working Group.
Trump 2.0's DOJ: White-Collar Enforcement Is Alive And Well
GP Goodwin Procter LLP More At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries.
Trump 2.0’s DOJ: White-Collar Enforcement is Alive and Well | JD Supra
Citing the need to strike a balance between “overbroad and unchecked corporate and white-collar enforcement [that] burdens U.S. businesses and harms U.S. interests” and “[u]nchecked fraud in U.S. markets and government programs [that] robs hardworking Americans and harms the public fisc,” on May 12, 2025, the Department of Justice (“DOJ”) issued guidance outlining the Criminal Division’s enforcement priorities and policies for prosecuting corporate and white-collar crime in the second Trump...
Health Headlines: February 2025
Your monthly Rx for private equity, regulatory and compliance, and digital health updates. Welcome to the third issue of Health Headlines, a newsletter created by lawyers in our Healthcare practice.
First Circuit Adopts Defense-Friendly "But-For" Causation Standard For AKS-Predicated FCA Claims
In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of the Anti-Kickback Statute (“AKS”),1 require proof that alleged kickbacks were the “but-for” cause of the challenged claims.2 Put another way, the government bears the burden “of proving that an AKS violation actually caused a physician to provide different medical treatment (and thus caused the false claims).”3 Under a 2010 amendment to the statute (42 U.S.C....
First Circuit Adopts Defense-Friendly “But-For” Causation Standard for AKS-Predicated FCA Claims | JD Supra
In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of the Anti-Kickback Statute (“AKS”),1 require proof that alleged kickbacks were the “but-for” cause of the challenged claims.2 Put another way, the government bears the burden “of proving that an AKS violation actually caused a physician to provide different medical treatment (and thus caused the false claims).”3 Under a 2010 amendment to the statute (42 U.S.C....
Florida District Court Concludes FCA's Qui Tam Provision Is Unconstitutional
On September 30, 2024, a federal judge for the Middle District of Florida issued a groundbreaking decision invalidating the qui tam provision of the False Claims Act ("FCA") as unconstitutional because the relator (or whistleblower) bringing such a suit qualifies as an "Officer" of the executive branch who was "improperly appointed" in violation of the Appointments Clause of Article II of the Constitution. U.S. ex rel. Zafirov v.
Florida District Court Concludes FCA’s Qui Tam Provision Is Unconstitutional | JD Supra
On September 30, 2024, a federal judge for the Middle District of Florida issued a groundbreaking decision invalidating the qui tam provision of the False Claims Act (“FCA”) as unconstitutional because the relator (or whistleblower) bringing such a suit qualifies as an “Officer” of the executive branch who was “improperly appointed” in violation of the Appointments Clause of Article II of the Constitution. U.S. ex rel. Zafirov v.
A deep dive into the Foreign Corrupt Practices Act
This is an Insight article, written by a selected partner as part of GIR's co-published content. Read more on Insight US enforcement authorities have several options available to them in resolving Foreign Corrupt Practices Act (FCPA) investigations – among them imposing an independent compliance monitor to oversee the company’s anti-bribery and anti-corruption compliance programme. Historically, FCPA investigations have frequently resulted in the imposition of compliance monitorships.
In Continuing Efforts To Incentivize Self-Disclosures And Cooperation, DOJ Announces Pilot Program To Pay Criminal Whistleblowers
Over the last few years, the U.S. Department of Justice ("DOJ") has continuously announced significant policies and programs directed at encouraging and rewarding the timely reporting of corporate wrongdoing, incentivizing compliance, and holding culpable individuals personally accountable. In a speech on March 7, 2024, Deputy Attorney General Lisa O. Monaco announced a new pilot program to financially compensate individual whistleblowers who report evidence of white collar crimes.
A Practical Look at OIG’s New Compliance Guidance | JD Supra
On November 6, 2023, for the first time in 15 years, HHS OIG issued a new reference guide for the health care compliance community – the General Compliance Program Guidance, or GCPG. While the GCPG does not set new legal standards and largely reinforces existing guidance, it is a tremendous tool to help health care and life sciences companies advance their compliance efforts.
DOJ Announces Safe Harbor Policy For M&A Self-Disclosures
On October 4, 2023, the United States Department of Justice (DOJ) announced a "safe harbor" policy for companies that voluntary self-disclose violations identified during the M&A process. US Deputy Attorney General Lisa Monaco, announcing the policy in a speech before the Society of Corporate Compliance and Ethics, said the safe harbor will apply to companies that self-report potential violations of an acquisition's target business when disclosed within six months of the deal's closing.
"Greenfield Fraught With Problems": District Of Massachusetts Holds But-For Causation Required In False Claims Act Cases Based On Kickbacks
On September 27, 2023, the Chief Judge of the District of Massachusetts decided that the standard in False Claims Act ("FCA") cases premised on alleged violations of the Anti-Kickback Statute ("AKS") is but-for causation. Breaking with the oft-cited 2018 Third Circuit case, United States ex rel. Greenfield v. Medco Health Solutions and prior District of Massachusetts decisions, the Court aligned with the standard more recently applied by the Eighth and Sixth Circuits.
“Greenfield Fraught with Problems”: District of Massachusetts Holds But-For Causation Required in False Claims Act Cases Based on Kickbacks | JD Supra
On September 27, 2023, the Chief Judge of the District of Massachusetts decided that the standard in False Claims Act (“FCA”) cases premised on alleged violations of the Anti-Kickback Statute (“AKS”) is but-for causation. Breaking with the oft-cited 2018 Third Circuit case, United States ex rel. Greenfield v. Medco Health Solutions and prior District of Massachusetts decisions, the Court aligned with the standard more recently applied by the Eighth and Sixth Circuits.
DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting | JD Supra
On February 22, 2023, the US Department of Justice (DOJ) a Voluntary Self-Disclosure Policy (VSD Policy) to formalize DOJ’s efforts to incentivize companies to voluntarily self-report criminal misconduct to the government. The VSD Policy, which is effective immediately and applies to all US Attorney’s Offices (USAO) nationwide, standardizes how DOJ defines corporate voluntary self-disclosure and offers significant benefits to companies that meet the VSD Policy’s exacting criteria.
Limiting PE Firms’ Exposure to FCA Liability for Alleged Misconduct by Portfolio Companies | JD Supra
There are many concerns that can keep private equity (PE) firms’ management teams up at night. Economic headwinds, geopolitical instability, and supply chain problems can change the fortunes of a PE firm and its portfolio companies seemingly overnight. Unfortunately for those PE executives already struggling with these challenges, there’s an increasingly prevalent concern rearing its ugly — and potentially costly — head: exposure to liability under the False Claims Act (FCA).
OIG: Continuing Education Programs Have Independent Value Under AKS | JD Supra
In the wake of the global pandemic, which forced manufacturers, trade organizations, and all other players in the health care industry to rethink how to provide medical education and communication on new product offerings to health care providers and consumers, the Department of Health and Human Services Office of Inspector General (OIG) recently weighed in on the potential inducement implications involved with manufacturer-sponsored continuing education.
2022 Updates to the AdvaMed Code: What You Need to Know | JD Supra
On March 18, the Advanced Medical Technology Association (AdvaMed) announced revisions to its Code of Ethics on Interactions with Health Care Professionals (AdvaMed Code or Code), last revised January 1, 2020. The new version of the AdvaMed Code will go into effect on June 1, 2022. AdvaMed's revisions are intended to provide useful and practical guidance to companies as they consider new ethical questions.
DOJ Announces Major Changes to Its Corporate Enforcement Policies | JD Supra
The Department of Justice (DOJ) has once again raised the bar for corporations seeking cooperation credit in government investigations.
The AKS "Means What It Says" — But Some Manufacturers and Patients Are Still Between a Rock and a Hard Place on Copay Assistance | JD Supra
In a highly watched case relating to the ability of pharmaceutical manufacturers to support patient copay assistance, the Southern District of New York recently denied Pfizer's request for a declaratory judgment that two proposed patient assistance programs would not violate the Anti-Kickback Statute (AKS).
The Case for Early-Stage Compliance
The year is 2012, and the biotech you founded has just received FDA approval for a wildly promising product with significant differentiation from other products in its class. You only have 35 employees, but begin to build a lean, incentive-based salesforce to launch your novel commercialization strategy built on a specialty distribution model, high-touch reimbursement support, aggressive marketing tactics, and premium pricing. Hiring a compliance officer is not a priority at this time.
The Case for Early-Stage Compliance | JD Supra
The year is 2012, and the biotech you founded has just received FDA approval for a wildly promising product with significant differentiation from other products in its class. You only have 35 employees, but begin to build a lean, incentive-based salesforce to launch your novel commercialization strategy built on a specialty distribution model, high-touch reimbursement support, aggressive marketing tactics, and premium pricing. Hiring a compliance officer is not a priority at this time.
Recent Developments in Auditing Could Create Tensions, Leading to More Regulatory Actions | JD Supra
Public companies should prepare for a more strenuous auditing process, and the increased likelihood that the information that they share with their auditors could be compelled by the Securities and Exchange Commission (SEC) during an investigation.
DC Taxpayers Face More Scrutiny Under New False Claims Act | JD Supra
On Jan. 13, 2021, District of Columbia Mayor Muriel Bowser signed the False Claims Amendment Act,[1] which expanded liability under the Washington, D.C., False Claims Act, or FCA, to encompass tax-related claims. The amendment is effective unless Congress jointly disapproves it during a 30-day review period currently underway.[2] It enables the D.C. attorney general to bring a new category of D.C. FCA cases and incentivizes private citizen whistleblowers to file more qui tam complaints.
New York Receives $105 Million In Tax Revenue And Damages Under False Claims Statute, While Other States Take Steps To Remove Their Tax Bar
United States: New York Receives $105 Million In Tax Revenue And Damages Under False Claims Statute, While Other States Take Steps To Remove Their Tax Bar 12 May 2021 by Amy Pritchard Williams , Ryan J. Strasser , Miranda Hooker and Rachel Miklaszewski Troutman Pepper Hamilton Sanders Your LinkedIn Connections with the authors To print this article, all you need is to be registered or login on Mondaq.com.
New York Receives $105 Million in Tax Revenue and Damages Under False Claims Statute, While Other States Take Steps to Remove Their Tax Bar | JD Supra
In early March, New York State Attorney General Letitia James and New York City Corporation Counsel John E. Johnson announced a $105 million settlement against a hedge fund manager for tax evasion. The New York authorities were alerted to the potential of fraud in October 2018 by a whistleblower lawsuit brought under New York’s False Claims Act (FCA). This settlement adds to the more than $460 million in tax-related false claim settlements the state has collected to date.
DOJ’s Robust 2020 Pandemic Response Signals Increasing Focus on COVID-19-Related Fraud in 2021 | JD Supra
Who Needs to Know All Corporations. Why It Matters As evidenced in the recently published 2020 Year in Review Report (Report), the Department of Justice's Fraud Section (Fraud Section) demonstrated its resilience despite the COVID-19 pandemic, as well as its swift response to the evolution of pandemic-induced fraud — a trend we expect will continue throughout 2021.
DC Taxpayers Face More Scrutiny Under New False Claims Act
Law360 (February 18, 2021, 4:54 PM EST) -- On Jan. 13, 2021, District of Columbia Mayor Muriel Bowser signed the False Claims Amendment Act,[1] which expanded liability under the Washington, D.C., False Claims Act, or FCA, to encompass tax-related claims.
Amending DC’s False Claims Act: Expansion of the DC AG’s Power Through Removal of the Tax Bar | JD Supra
On January 13, District of Columbia Mayor Muriel Bowser signed the False Claims Amendment Act of 2020 (the Amendment), which expanded liability under the D.C. False Claims Act (D.C. FCA) to encompass tax-related claims. The Amendment is effective unless Congress jointly disapproves it during a 30-day review period.
Anti-Kickback Statute Enforcement Year in Review and Outlook for 2021 | JD Supra
I. Introduction While 2020 was a year like no other in many ways, the challenges posed by the global COVID-19 pandemic do not appear to have stalled the Department of Justice's (DOJ) health care fraud enforcement activities. Indeed, in fiscal year 2020, DOJ recovered more than $2.2 billion in False Claims Act (FCA) cases, with $1.8 billion of that amount coming from the health care industry.
Borrower Beware: First False Claims Act PPP Loan Fraud Settlement Signals More to Come | JD Supra
The Department of Justice (DOJ) entered into its first civil settlement for loan fraud involving the Paycheck Protection Program (PPP). On January 12, the U.S. Attorney's Office for the Eastern District of California announced that Slidebelts, Inc. and its president and CEO, Brigham Taylor, agreed to pay $100,000 in damages and penalties to resolve civil fraud allegations for misrepresenting their bankruptcy to obtain a $350,000 PPP loan.
Fraud Emerges as Telemedicine Surges: Compliance Guidance for Telemedicine Providers | JD Supra
Who Needs to Know All telemedicine providers. Why It Matters Telemedicine providers – whether they are established or new to the space – should examine the type of conduct DOJ has recently focused on and adapt their compliance systems accordingly. Providers should also consider the cybersecurity dimension of a robust compliance system and ensure that their network is protected from malicious cyber actors exploiting deficiencies in many popular telework platforms.
FDA Launches Digital Center of Excellence and ONC Updates HIPAA Security Risk Assessment Tool | JD Supra
Who Needs to Know Health Care and Life Sciences Organizations Why It Matters In order to safeguard their information, health care and life science organizations should remain vigilant in monitoring DHCoE developments and initiatives, including any policy/regulation clarifications related to digital health. They also should consider reviewing the SRA Tool to help conduct security risk assessments to better protect the personal health data entrusted to them.
Did Congress Intend to Criminalize Off-Label Promotion? One District Judge Suggests the Issue Is Ripe for Review | JD Supra
A judge in the District of Massachusetts recently questioned whether Congress intended to criminalize off-label promotion through misbranding and adulteration statutes. In an order denying a Rule 29 motion brought by two former Acclarent executives, U.S. District Judge Allison D. Burroughs wrote, “It seems clear that the statutory and regulatory scheme needs to be rethought.
Can Compliance Negate Intent? The Case for Continuously Customizing Compliance Programs | JD Supra
Recently, the Department of Justice (DOJ) updated its “ Evaluation of Corporate Compliance Programs” guidance — the third iteration of DOJ’s guidance on this topic. The update is intended to offer transparency as to how DOJ views compliance and cooperation in the context of government investigations. Much has been written about the fundamentals of the revised guidance since its publication in June and how companies should evaluate their compliance programs against the benchmark of DOJ’s guidance.
False Claims Act Update: Third Circuit Widens First-to-File Circuit Split | JD Supra
Last week, in the In re Plavix decision, the Third Circuit addressed the question of whether relators can be added or substituted in an amended complaint and, in the process, weighed in on whether the first-to-file bar is jurisdictional. Widening an existing circuit split on the issue, the court held that the first-to-file bar is nonjurisdictional and that a first-to-file challenge must be brought in a motion to dismiss under Federal Rule of Civil Procedure 12(b)(6).
Protecting Trade Secrets: Lessons Learned From the Levandowski Case | JD Supra
Companies often consider trade secrets to be their crown jewels. But in the digital age, where copying and sending files is as easy as one click, protecting trade secrets has become even more challenging. Losing control over a trade secret can mean losing the edge over competitors or possibly the entire value of a product or a company.
It’s All Hands on Deck in Prosecuting COVID-19 Fraud | JD Supra
As scientists around the globe team up to discover and develop treatments and vaccine candidates for COVID-19, we are also seeing unprecedented speed and coordination in the effort to quell a different kind of virus — the myriad fraud schemes stemming from the COVID-19 crisis.
Trying Times For Nursing Homes: How Increased Compliance Practices Can Stem The Next Wave Of DOJ Enforcement | JD Supra
As the world’s health care facilities grapple with the devastating and unexpected operational struggles brought by COVID-19, nursing homes and long-term care facilities face the added challenge of protecting their residents and staff against COVID-19 while under the federal enforcement microscope.
The Coming Tsunami: Anticipated Regulatory and Enforcement Trends in the Wake of COVID-19 and the Unique Role of State Attorneys General
Throughout the 20th and 21st centuries, every national crisis in the United States has left a long wake of investigations in its trail at all levels of government. Those governmental investigations and enforcement actions have followed a familiar pattern when arising out of a public crisis. First, investigative and regulatory bodies at both the federal and state levels target the obvious scammers.
Lessons From the DOJ: How Recent Guidance and Cases Can Help You Avoid Government Interference With Your Business | JD Supra
The initiation of a government investigation is often a stressful and anxiety-producing event for a health care company. The Department of Justice (DOJ) is known for its aggressive investigation and prosecution of health care fraud and related offenses, and the potential penalties can have a significant impact on the livelihood and future of a company.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Miranda
Contact Miranda, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack